Novavax reported $298.02M in Sales Revenues for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Adamas Pharmaceuticals ADMS:US 21.97M 2.66M
Adma Biologics ADMA:US $ 17.83M 1.78M
Agenus AGEN:US $ 10.73M 0.99M
Astrazeneca AZN:US $ 8220M 900M
AstraZeneca AZN:LN 8220M 900M
Biocryst Pharmaceuticals BCRX:US $ 49.96M 30.9M
BioSpecifics Technologies BSTC:US 11.26 7.35
Dynavax Technologies DVAX:US $ 52.77M 30.57M
Geron GERN:US $ 0.11M 0.03M
GlaxoSmithKline GSK:LN 8092M 674M
Kindred Biosciences KIN:US $ 3.54M 1.14M
Mannkind MNKD:US $ 23.28M 5.84M
Merk MRK:US $ 11402M 678M
Moderna Inc MRNA:US 4.35B 2.42B
Novartis NVS:US $ 13294M 600M
Novavax NVAX:US $ 298.02M 149.21M
Peregrine Pharmaceuticals PPHM:US $ 30.75M 3.15M
Pfizer PFE:US $ 18977M 4395M
Sarepta Therapeutics SRPT:US $ 164.09M 17.16M
Tg Therapeutics TGTX:US $ 1.54M 0.75M